Artivion (NYSE:AORT) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Artivion (NYSE:AORT) in a report issued on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $58.00 price objective on the stock.

AORT has been the topic of several other reports. Canaccord Genuity Group decreased their price target on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. Stifel Nicolaus set a $55.00 price target on shares of Artivion in a research note on Thursday, March 5th. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Finally, Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $50.47.

Artivion Trading Up 5.2%

NYSE AORT opened at $35.18 on Tuesday. The stock’s 50-day simple moving average is $37.39 and its two-hundred day simple moving average is $41.79. Artivion has a twelve month low of $21.97 and a twelve month high of $48.25. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of 175.92 and a beta of 1.63.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.14 by $0.03. The firm had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The firm’s revenue for the quarter was up 19.2% compared to the same quarter last year. Research analysts forecast that Artivion will post 0.37 EPS for the current fiscal year.

Insider Activity

In related news, insider John E. Davis sold 4,573 shares of Artivion stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $172,767.94. Following the transaction, the insider directly owned 230,794 shares of the company’s stock, valued at $8,719,397.32. The trade was a 1.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jean F. Holloway sold 8,962 shares of Artivion stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total transaction of $340,556.00. Following the completion of the transaction, the senior vice president directly owned 185,095 shares in the company, valued at approximately $7,033,610. The trade was a 4.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 133,043 shares of company stock valued at $4,977,158 in the last three months. Corporate insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Aster Capital Management DIFC Ltd increased its holdings in Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Artivion during the 3rd quarter valued at about $27,000. Rockefeller Capital Management L.P. increased its holdings in Artivion by 150.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after purchasing an additional 399 shares during the period. Larson Financial Group LLC increased its holdings in Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after purchasing an additional 563 shares during the period. Finally, USA Financial Formulas increased its holdings in Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after purchasing an additional 703 shares during the period. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.